Next-Step Treatment Options for Treatment-Resistant Depression
Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
Authors
- Melanie T. Gentry (ORCID: https://orcid.org/0000-0002-9484-3206)
- Simon Kung (ORCID: https://orcid.org/0000-0002-2959-8312)
- Paul E. Croarkin (ORCID: https://orcid.org/0000-0001-6843-6503)
- Brandan Penaluna
- Hannah K. Betcher
- Stefanie Cavalcanti (ORCID: https://orcid.org/0000-0002-4806-8149)
- Marin Veldić (ORCID: https://orcid.org/0000-0002-7651-9197)
- Katherine M. Moore
- Balwinder Singh
- Matheus G. Marques
- Mark A. Frye
- Aysegul Özerdem
- Jennifer L. Vande Voort
Institutions
- Mayo Clinic (US)
- Singer (United States) (US)
Publication Details
- Journal
- The Journal of Clinical Psychiatry
- Published
- 2026-01-20
- DOI
- https://doi.org/10.4088/jcp.25cs16066
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00